Abstract:Duanduan Cong, 1 Wenyuan Qi, 1 Xiaohui Liu, 1 Xiaoyu Xu, 1 Lingyun Dong, 2 Wei Xue, 1, &ast Kexin Li 1, &ast 1 Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation, Beijing, People's Republic of China; 2 Beijing Yeedozencom Healthcare Science & Technology Co., Ltd, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Xue; Kexin Li, Clinical Trial Centre (The North Building B4), Beijing Hospital, No. 1 Dahua Road, Dongdan, Dongcheng District, Beijing, 100730, People's Republic of China, Tel +861085133632, Email ; Purpose: To study and compare the pharmacokinetic characteristics of enteric-coated sustained-release (EcSr) aspirin tablets with enteric-coated (Ec) aspirin tablets (Bayer S.p.A) in healthy Chinese participants. Patients and Methods: In this open, randomized, single-dose, three-way, crossover study, 18 healthy participants randomly received 100 mg EcSr tablets pre-prandially (a.c.), EcSr tablets post-prandially (p.c.), or Ec tablets a.c. in each period. The concentrations of acetylsalicylic acid (ASA) and salicylic acid (SA) in plasma were determined by the LC-MS/MS method, and the pharmacokinetic parameters were calculated using WinNonlin (version 8.1). Results: The essential PK parameters under the three treatment conditions (ie Ec a.c., EcSr a.c. and EcSr p.c.) were as follows: C max, ASA : 758.38± 455.34, 222.77± 98.04 and 194.54± 61.19 ng, T max, ASA : 6.75(2,16), 4.5(2,11) and 8.25(5,11) h, T 1/2, ASA : 0.43± 0.08, 1.44± 0.59 and 4.32± 10.04 h, AUC 0-t, ASA : 1008.88± 452.27, 918.04± 238.40 and 845.55± 183.25 h·ng/mL; C max, SA : 6409.38± 2098.52, 2863.53± 679.73 and 2913.75± 853.27ng/mL, T max, SA : 7.25(2,24), 10(3.5– 14) and 10(7,14) h, T1/2, SA: 2.21± 0.46, 2.69± 0.72 and 3.51± 2.06h, AUC 0 – t, SA : 29,131.41± 9376.23, 27,243.97± 7465.16, 27,240.25± 7444.67 h·ng/mL. When taking EcSr aspirin tablets, the 90% confidence intervals of the geometric mean ratios (pre-prandial/post-prandial) of AUC 0-t, ASA and AUC 0–∞, ASA , C max, SA , AUC 0-t, SA and AUC 0–∞, SA were within the range of 80.00%– 125.00%. Conclusion: EcSr aspirin tablets showed less inter-individual variation in release and absorption than Ec aspirin tablets, which was well reflected by comparing essential PK parameters. Furthermore, meals had no significant effect on the pharmacokinetics of EcSr aspirin tablets. Keywords: acetylsalicylic acid, salicylic acid, enteric-coated sustained-release, pharmacokinetics Aspirin (acetylsalicylic acid) is a classic non-steroidal anti-inflammatory drug which can be rapidly hydrolysed to salicylic acid after oral administration. It exerts various pharmacological effects depending on the dose, with low doses of 75–100 mg usually used to prevent and treat cardiovascular diseases. In that case, aspirin works mainly by irreversibly inhibiting the function of cyclooxygenase in platelets, preventing them from aggregation and thrombosis. 1 However, in recent years, studies have found that taking very low doses of aspirin (daily or every other day ≤100mg) could still significantly increase the risk of major gastrointestinal bleeding and haemorrhagic stroke. Especially in the primary prevention of cardiovascular diseases, the benefits of aspirin therapy do not significantly outweigh the risk of bleeding. 2 Aspirin enteric-coated (EC) tablets are currently the dosage form with the highest market share. This dosage form reduces direct irritation to the gastric mucosa by avoiding decomposition in the stomach. However, apart from directly stimulating the gastric mucosa, aspirin can still produce systemic effects that inhibit the synthesis of gastric mucosal protective factors prostacyclin (prostaglandin I2, PGI 2 ) and prostaglandin E2 (Prostaglandin E2, PGE 2 ). Consequently, in clinical practice, enteric-coated tablets cannot effectively reduce the risk of gastric mucosal damage, ulcers and bleeding. 3 Therefore, there is still an unmet clinical need to develop novel aspirin dosage forms with better benefit-risk profiles to treat and prevent cardiovascular and cerebrovascular diseases. Another unique aspirin dosage form, aspirin enteric-coated sustained-release (EcSr) tablets developed by Shandong Xinhua Pharmaceutical Co., Ltd. (Brand name: JieNing ® ), has been on the market for many y -Abstract Truncated-

Relative bioavailability of dipyridamole compound recipe extended-release capsules in healthy volunteers

Determination of Dipyridamole and Salicylic Acid in Compound Dipyridamole Sustained-release Capsules by HPLC and Study on Its Bioequivalence

Study on bioequivalence of cilostazol table in healthy volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Relative bioavailability of disodium etidronate capsules in healthy volunteers

Bioequivalence Study Comparing Fixed-Dose Combination of Clopidogrel and Aspirin with Coadministration of Individual Formulations in Chinese Subjects Under Fed Conditions: A Phase I, Open-Label, Randomized, Crossover Study

Pharmacokinetic and Bioequivalence Evaluation of Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate, and Aspirin Tablets in Healthy Chinese Subjects in the Fasting and Postprandial Conditions

Study on the Pharmacokinetics and Bioequivalence of Isosorbide 5-Mononitrate and Aspirin from Compound Isosorbide Mononitrate Sustained Release Tablets in Healthy Volunteers

Relative bioavailability and bioequivalence of clopidogrel hydrogen sulfate tablets in healthy volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Kinetics of aspirin, salicylic acid, and salicyluric acid following oral administration of aspirin as a tablet and two buffered solutions.

Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation

P1935Pharmacokinetic and pharmacodynamic assessment of a lipid-based aspirin formulation: results of a prospective, randomised, crossover study

Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers

Relative Bioavailability of Ibuprofen Sustained-release Capsules in Human Subjects

Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Oral Formulations of Calcium Dobesilate Capsules in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic Acid) Plus Extended-Release Dipyridamole Are Not Altered by Coadministration with the Potent CYP2C19 Inhibitor Omeprazole

Bioequivalence and Pharmacodynamics of a Generic Dabigatran Etexilate Capsule in Healthy Chinese Subjects under Fasting and Fed Conditions

Bioequivalence of Two Cilnidipine Formulations in Healthy Chinese Volunteers

Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets in Healthy Chinese Participants